There is a dire need for novel therapies to improve outcomes for patients with Alzheimer’s Disease, which is considered one of the fastest-growing health threats of our time.
In a promising new study published in the Journal of Alzheimer’s Disease, investigators reported that a two-week course of high dose CBD helped reduce plaque and improve cognitive function in an experimental model of early onset familial AD.
Familial disease is an inherited version of Alzheimer’s in which symptoms typically surface in the 30s and 40s and occurs in about 10-15% of patients.
Next steps include determining optimal doses and giving CBD earlier in the disease process. They also are exploring delivery systems including the use of an inhaler that should help deliver the CBD more directly to the brain.
See article below for more information. https://www.sciencedaily.com/releases/2021/03/210309192548.htm Citation for journal article, available here https://pubmed.ncbi.nlm.nih.gov/33612548/